+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Proton pump inhibitors: predisposers to Alzheimer disease?



Proton pump inhibitors: predisposers to Alzheimer disease?



Journal of Clinical Pharmacy and Therapeutics 35(2): 125-126



The abnormal processing of amyloid-beta peptide (A beta) and resultant formation of fibrillar A beta (fA beta) are major events in the pathogenesis of Alzheimer disease (AD). Microglia as the phagocytic cells of the brain can engulf and digest fA beta within their acidic lysosomes. The lysosomes of AD patients are less acidic and therefore less capable of clearance of fA beta. Vacuolar proton pumps (V-ATPases) which are found abundantly in microglia and macrophages, acidify lysosomes by pumping protons into these structures. Proton pump inhibitors (PPIs) can inhibit V-ATPases of the lysosomes. These drugs are shown to penetrate the blood-brain barrier in animals. PPIs are consumed for long periods in conditions such as gastroesophageal reflux disease, with the resultant exposure of the human brain to the substantial amounts of PPIs. We hypothesize that by blocking the V-ATPases on microglial lysosomes, PPIs may basify lysosomes and hamper degradation of fA beta. Chronic consumption of PPIs may thus be a risk factor for AD.

(PDF emailed within 0-6 h: $19.90)

Accession: 055260422

Download citation: RISBibTeXText

PMID: 20456731

DOI: 10.1111/j.1365-2710.2009.01100.x


Related references

Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study. Journal of Gastroenterology 2019, 2019

Long-term use of proton pump inhibitors among community-dwelling persons with and without Alzheimer's disease. European Journal of Clinical Pharmacology 73(9): 1149-1158, 2017

Is the Use of Proton-pump Inhibitors a Risk Factor for Alzheimer's Disease? Molecular Mechanisms and Clinical Implications. Current Medicinal Chemistry 25(18): 2166-2174, 2018

Prevention of stress induced ulcers: histamine-2 receptor antagonists or proton pump inhibitors? - gastric hemorrhage occur more often under proton pump inhibitors. Deutsche Medizinische Wochenschrift 139(25-26): 1338, 2014

Risk of small intestinal bacterial overgrowth in patients receiving proton pump inhibitors versus proton pump inhibitors plus prokinetics. Jgh Open 2(2): 47-53, 2018

Hypersensitivity to lansoprazole with tolerance to other proton pump inhibitors: does cross-reactivity between proton pump inhibitors really exist?. Allergologia et Immunopathologia 41(2): 136-137, 2013

When proton pump inhibitors are compared, are there specific cases in which a certain proton pump inhibitors should be particularly preferred?. Turkish Journal of Gastroenterology 28(Suppl 1): S68-S70, 2018

Case report of proton pump inhibitor responsive esophageal eosinophilia: why 2 months of proton pump inhibitors is required. Diseases of the Esophagus 29(6): 700-703, 2017

Revealing the Mechanistic Pathway of Acid Activation of Proton Pump Inhibitors To Inhibit the Gastric Proton Pump: A DFT Study. Journal of Physical Chemistry. B 120(51): 13031-13038, 2016

Correlation between acid secretion and proton pump activity during inhibition by the proton pump inhibitors omeprazole and pantoprazole. Biochemical Pharmacology 58(8): 1349-1359, Oct 15, 1999

Proton pump inhibitors partially restore mucosal integrity in patients with proton pump inhibitor-responsive esophageal eosinophilia but not eosinophilic esophagitis. Clinical Gastroenterology and Hepatology 12(11): 1815-23.E2, 2015

Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding. Journal of Gastroenterology 46(1): 39-45, 2011

Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Alimentary Pharmacology and Therapeutics 17(2): 259-264, 2003

Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo-β-N-acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease. Bioorganic and Medicinal Chemistry Letters 27(13): 2962-2966, 2017

Proton Pump Inhibitors in Kidney Disease. Clinical Journal of the American Society of Nephrology 13(10): 1458-1459, 2018